Mesenchymal Stem Cells as a Biological Drug for Heart Disease: Where Are We with Cardiac Cell-Based Therapy?

Cristina Sanina, Joshua M. Hare

Research output: Contribution to journalArticle

Abstract

Cell-based treatment represents a new generation in the evolution of biological therapeutics. A prototypic cell-based therapy, the mesenchymal stem cell, has successfully entered phase III pivotal trials for heart failure, signifying adequate enabling safety and efficacy data from phase I and II trials. Successful phase III trials can lead to approval of a new biological therapy for regenerative medicine.

Original languageEnglish (US)
Pages (from-to)229-233
Number of pages5
JournalCirculation Research
Volume117
Issue number3
DOIs
StatePublished - Jul 17 2015
Externally publishedYes

Fingerprint

Cell- and Tissue-Based Therapy
Mesenchymal Stromal Cells
Heart Diseases
Biological Evolution
Biological Therapy
Regenerative Medicine
Pharmaceutical Preparations
Heart Failure
Safety
Therapeutics

Keywords

  • cell- and tissue-based therapy
  • chronic heart failure
  • clinical trial
  • heart disease
  • mesenchymal stem cells

ASJC Scopus subject areas

  • Physiology
  • Cardiology and Cardiovascular Medicine

Cite this

Mesenchymal Stem Cells as a Biological Drug for Heart Disease : Where Are We with Cardiac Cell-Based Therapy? / Sanina, Cristina; Hare, Joshua M.

In: Circulation Research, Vol. 117, No. 3, 17.07.2015, p. 229-233.

Research output: Contribution to journalArticle

@article{871175c019a64b07a8b991e5d2c6df6a,
title = "Mesenchymal Stem Cells as a Biological Drug for Heart Disease: Where Are We with Cardiac Cell-Based Therapy?",
abstract = "Cell-based treatment represents a new generation in the evolution of biological therapeutics. A prototypic cell-based therapy, the mesenchymal stem cell, has successfully entered phase III pivotal trials for heart failure, signifying adequate enabling safety and efficacy data from phase I and II trials. Successful phase III trials can lead to approval of a new biological therapy for regenerative medicine.",
keywords = "cell- and tissue-based therapy, chronic heart failure, clinical trial, heart disease, mesenchymal stem cells",
author = "Cristina Sanina and Hare, {Joshua M.}",
year = "2015",
month = "7",
day = "17",
doi = "10.1161/CIRCRESAHA.117.306306",
language = "English (US)",
volume = "117",
pages = "229--233",
journal = "Circulation Research",
issn = "0009-7330",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Mesenchymal Stem Cells as a Biological Drug for Heart Disease

T2 - Where Are We with Cardiac Cell-Based Therapy?

AU - Sanina, Cristina

AU - Hare, Joshua M.

PY - 2015/7/17

Y1 - 2015/7/17

N2 - Cell-based treatment represents a new generation in the evolution of biological therapeutics. A prototypic cell-based therapy, the mesenchymal stem cell, has successfully entered phase III pivotal trials for heart failure, signifying adequate enabling safety and efficacy data from phase I and II trials. Successful phase III trials can lead to approval of a new biological therapy for regenerative medicine.

AB - Cell-based treatment represents a new generation in the evolution of biological therapeutics. A prototypic cell-based therapy, the mesenchymal stem cell, has successfully entered phase III pivotal trials for heart failure, signifying adequate enabling safety and efficacy data from phase I and II trials. Successful phase III trials can lead to approval of a new biological therapy for regenerative medicine.

KW - cell- and tissue-based therapy

KW - chronic heart failure

KW - clinical trial

KW - heart disease

KW - mesenchymal stem cells

UR - http://www.scopus.com/inward/record.url?scp=84937554663&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84937554663&partnerID=8YFLogxK

U2 - 10.1161/CIRCRESAHA.117.306306

DO - 10.1161/CIRCRESAHA.117.306306

M3 - Article

C2 - 26185208

AN - SCOPUS:84937554663

VL - 117

SP - 229

EP - 233

JO - Circulation Research

JF - Circulation Research

SN - 0009-7330

IS - 3

ER -